Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01787240 · ClinicalTrials.gov registry record · Phase 4
Neurobiological Bases of Placebo Response in Major Depressive Disorder
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01787240: Clinical Trial Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01787240 is a Phase 4 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01787240, a Phase 4 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo (an inactive substance) have similar chemicals in their brains. Some participants may complete a procedure called Acute Tryptophan Depletion (ATD), which is a way to study the role of serotonin in depression. Some participants may also undergo a magnetic resonance-positron emission tomography (MR-PET) scan.
Interventions
- DRUG Placebo
- DRUG Escitalopram 10mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2012-11 |
| Est. Completion | 2016-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01787240
The ClinicalTrials.gov registry entry for NCT01787240 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01787240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01787240 about?
NCT01787240 is a clinical study titled "Neurobiological Bases of Placebo Response in Major Depressive Disorder". We are doing this research study to find out if people who get better while taking a specific kind of antidepressant medication (a selective serotonin reuptake inhibitor, or SSRI) and people who get better while taking placebo (an inactive substance) have similar chemicals in their brains. Some part...
What is the current status of trial NCT01787240?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2012-11. Estimated completion is 2016-08.
What interventions are being tested in trial NCT01787240?
The interventions under investigation include: Placebo (DRUG), Escitalopram 10mg (DRUG).
Who is sponsoring clinical trial NCT01787240?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.